Prognosis, imatinib dose, and benefit of sunitinib in GIST: Knowing the genotype

Journal of Clinical Oncology

Volumn 26, Issue 33, 2008, Pages 5322-5325

  Judson, Ian R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; MOTESANIB; PLACEBO; SUNITINIB; VASCULOTROPIN RECEPTOR;

CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; GENOTYPE; HUMAN; KIT GENE; MAXIMUM TOLERATED DOSE; NONHUMAN; PDGFRA GENE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MUTATION; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 56749098279     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.7725     Document Type: Editorial

References (28)

1. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004
2. Blanke CD, Rankin C, Demetri GD, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632, 2008
3. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
4. Verweij J, van Oosterom A, Blay JY, et al: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006-2011, 2003
5. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
6. Blanke CD, Demetri GD, von Mehren M, et al: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620-625, 2008
7. Zalcberg JR, Verweij J, Casali PG, et al: Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751-1757, 2005
8. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 279:577-580, 1998
9. Lux ML, Rubin BP, Biase TL, et al: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156:791-795, 2000
10. Heinrich MC, Corless CL, Duensing A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710, 2003
11. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003
12. Debiec-Rychter M, Sciot R, Le Cesne A, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103, 2006
13. Heinrich, MC, Owzar K, Corless L, et al: Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol doi;10.1200/JCO.2008.17.4284
14. Van Glabbeke M, Owzar K, Rankin C, et al: Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumor (GIST): A meta-analysis based on 1,640 patients. J Clin Oncol 25;546s, 2007 (suppl; abstr 10004)
15. Van Glabbeke M, Verweij J, Casali PG, et al: Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23:5795-5804, 2005
16. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813-3825, 2004
17. Desai J, Shankar S, Heinrich MC, et al: Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 13:5398-5405, 2007
18. Growney JD, Clark JJ, Adelsperger J, et al: Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106:721-724, 2005
19. Schittenhelm MM, Shiraga S, Schroeder A, et al: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66:473-481, 2006
20. Polverino A, Coxon A, Starnes C, et al: AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and KIT receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66:8715-8721, 2006
21. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
22. Maki RG, Fletcher JA, Heinrich MC, et al: Results from a continuation trial of SU11248 in patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 23;818s, 2005 (suppl; abstr 9011)
23. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
24. Heinrich MC, Maki RG, Corless CL, et al: Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correleates with KIT and PDGFRA mutation status. J Clin Oncol 24;520s, 2006 (suppl; abstr 9502)
25. Heinrich MC, Maki RG, Corless CL, et al: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol doi:10.1200/JCO.2007.15.7461
26. von Mehren M: Beyond imatinib: Second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer 6:S30-S34, 2006 (suppl 1)
27. Bauer S, Yu LK, Demetri GD, et al: Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66:9153-9161, 2006
28. Heinrich MC, Corless CL, Blanke CD, et al: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764-4774, 2006